DexCom price target lowered to $135 from $160 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on DexCom to $135 from $160 and keeps an Overweight rating on the shares. The firm said Q3 results beat “handily” on the top and bottom lines, adding that it views increased guidance as “readily achievable.” The big driver for the stock is basal access alongside a quickly expanding prescribing base, the analyst tells investors in a research note.